Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Stress Hyperglycemia. Potential Role of Incretin Analogs

This study has been completed.
Fundació Mateu Orfila
Information provided by:
Hospital Universitari Son Dureta Identifier:
First received: March 11, 2010
Last updated: June 7, 2010
Last verified: June 2010
This is a prospective observational study to examine the levels of glucoregulatory hormones, with special focus on incretins levels, in critically ill patients with stress hyperglycemia.

Critical Illness

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Stress Hyperglycemia in Critically Ill Patients. Potential Role of Incretin Analogs. A Preliminary Study

Resource links provided by NLM:

Further study details as provided by Hospital Universitari Son Dureta:

Primary Outcome Measures:
  • Incretins plasmatic levels [ Time Frame: 28 days ]
    28 days and ICU mortality

Secondary Outcome Measures:
  • glucagon [ Time Frame: 28 days ]
    28 days and ICU mortality

  • insulin [ Time Frame: 28 days ]
    28 days and ICU mortality

  • cortisol [ Time Frame: 28 days ]
    28 days and ICU mortality

  • HOMA index [ Time Frame: 28 days ]
    28 days and ICU mortality

Biospecimen Retention:   Samples Without DNA
Plasma and serum samples to analyze glucorregulatory hormones.

Estimated Enrollment: 60
Study Start Date: January 2010
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Medical-surgical ICU patients

Inclusion Criteria:

  • Age > 18 years
  • Emergent ICU admission
  • Written informed consent from patient or relative.

Exclusion Criteria:

  • Previously known type I or type II diabetes.
  • Patients who received insulin or oral antidiabetic agents before ICU admission.
  • Malignancies.
  • Scheduled surgery
  • Patients receiving enteral or parenteral nutrition.
  • Inability to obtain informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01087372

Hospital Universitari Son Dureta. Intensive Care Unit
Palma de Mallorca, Illes Balears, Spain, 07014
Sponsors and Collaborators
Hospital Universitari Son Dureta
Fundació Mateu Orfila
Principal Investigator: Juan A Llompart-Pou, M.D. Hospital Universitari Son Dureta. Intensive Care Unit
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Juan A Llompart-Pou, Hospital Universitari Son Dureta Identifier: NCT01087372     History of Changes
Other Study ID Numbers: Incretins2010
Study First Received: March 11, 2010
Last Updated: June 7, 2010

Keywords provided by Hospital Universitari Son Dureta:
Stress hyperglycemia
glucoregulatory hormones

Additional relevant MeSH terms:
Critical Illness
Glucose Metabolism Disorders
Metabolic Diseases
Disease Attributes
Pathologic Processes
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on May 25, 2017